Mallinckrodt plc MNK, will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter’s investigation into the acquisition of Synacthen Depot by its Questcor ...

Until now there has been no test that could detect synacthen, which when injected simulates the body to produce extra amounts of its own corticosteroid. This is most common in sports where sports ...

Shares of Questcor Pharmaceuticals, Inc. (QCOR) recently received a major boost when the company announced the acquisition of development and commercialization rights to Synacthen and Synacthen Depot ...

Injecting performance enhancing corticosteroid hormones for other than medical treatment is banned, and tests exist that can detect injected hormones. Injecting synacthen, which stimulates the body to ...

Questcor Pharmaceuticals said today it acquired rights to develop Synacthen® (tetracosactide) and Synacthen Depot in the U.S. from Novartis Pharma and parent company Novartis, in a deal that could net ...

Questcor's stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis' rival immune drug Synacthen. Questcor’s stock leapt nearly 40% during trading ...

This leaflet answers some common questions about Synacthen Depot. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines ...

An icon in the shape of a lightning bolt. Impact Link Mallinckrodt Pharmaceuticals' agreed to pay $100 million to settle Federal Trade Commission (FTC) charges it used its monopoly on a lupus and ...

Mallinckrodt announced that the FDA has granted Fast Track designation to the Investigational New Drug (IND) application of Synacthen Depot (tetracosactide) for the treatment of Duchenne muscular ...